Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
4
×
detroit top stories
fda
4
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
4
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
crispr
ipo
novartis
asklepios biopharmaceutical
biogen
cancer
celgene
crispr therapeutics
eli lilly
gene editing
gene therapy
gilead sciences
What
bio
new
4
×
roundup
4
×
crispr
ipo
isn’t
activity
allogene
approvals
bails
biogen
biopharma
brand
bridgebio
cancer
capital
car
clamped
congress
congressional
covid
delays
develop
developing
diversity
drugs
economic
emerges
executives
fast
fda
feud
firm
grab
group
headlines
hot
ichnos
immunotherapy
including
Language
unset
Current search:
fda
×
roundup
×
" detroit blog main "
×
new
×
" seattle blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More